Archive for the 'Erectile Dysfunction' Category
Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol To FDA
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). “The progression of Zoraxel’s clinical program is very encouraging,” said Rexahn Chief Executive Officer, Dr…Original post by Dental Heroes
No commentsUrologist Dr. J. Francois Eid, MD Warns Against The Dangers Of Online Herbal Remedies For Erectile Dysfunction (ED)
News reports coming out of the UK and Australia show evidence of prescription ingredients in many “natural” herb remedies sold on the Internet to treat erectile dysfunction (ED). These popular online supplements, which claim to consist only of homeopathic ingredients, are often improperly labeled and may actually contain dangerous ingredients. Dr. J…Original post by Dental Heroes
No commentsGlobal Health Ventures To Initiate Human Clinical Trials In Europe For X-Excite, Its Male Sexual Enhancement Drug
Global Health Ventures Inc. (OTCBB:GHLV), or the “Company”, is pleased to announce that it has engaged Clinical Investigations Ltd. of United Kingdom to design and carry out the human clinical trials for X-Excite in Europe under the European Regulatory Guidelines (EMEA)…Original post by Consumer Reports Health Blog
No commentsErectile Dysfunction As A Predictor For Subsequent Atherosclerotic Cardiovascular Events: Findings From A Linked-Data Study
UroToday.com - In permitting longitudinal data analyses of our study cohort of men with erectile dysfunction (ED) and without known previous history of cardiovascular (CV) disease, data linkage has provided us a novel methodological approach in our investigation on the role of ED as a predictor of atherosclerotic CV events…Original post by The Diabetes Blog
No commentsPalatin Technologies, Inc. Announces Dosing Of Subcutaneous Bremelanotide Trial In Men
Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old…Original post by Six Until Me.
No commentsDiscovery That Viagra Enhances Fetal Growth In Female Sheep May Have Human Implications
A joke among two Texas AgriLife Research scientists later turned into a fully-funded study. Viagra can aid fetal development in female sheep. Female sheep (ewes) are an agriculturally important species, which can serve as an excellent animal model for studying the physiology of human pregnancy, the researchers said…Original post by Annetics
No commentsSignificant Risks Posed By Counterfeit Internet Drugs
Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed. That’s the warning just published online by IJCP the International Journal of Clinical Practice…Original post by Lemonade Life
No commentsNERI Research Findings Show That Erectile Dysfunction May Be Early Warning Of Future Cardiovascular Disease
In the first study of its kind, New England Research Institutes, Inc…Original post by Lemonade Life
No commentsNexMed Updates On Canadian Aproval Process For Vitaros
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, announced today that it received a Notice of Non-Compliance (”Notice”) as part of the review process from Health Canada for its New Drug Submission (”NDS”) for the Vitaros erectile dysfunction treatment filed in February 2008…Original post by Lemonade Life
No commentsVIVUS Announces Additional Results Of Phase 3 Avanafil Study In Erectile Dysfunction Showing Efficacy In 15 Minutes
VIVUS, Inc. (Nasdaq: VVUS) announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED)…Original post by Healthcare IT News Blog
No comments